Pathstone Holdings
RDY icon

Pathstone Holdings’s Dr. Reddy's Laboratories RDY Stock Holding History

Pathstone Holdings’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Sell
95,197
-15,312
-14% -$207K ﹤0.01% 1339
2026
Q1 		$1.53M Sell
110,509
-2,814
-2% -$39.2K 0.01% 1183
2025
Q4 		$1.59M Buy
113,323
+5,523
+5% +$77.5K 0.01% 1159
2025
Q3 		$1.51M Sell
107,800
-3,223
-3% -$46.4K 0.01% 1178
2025
Q2 		$1.67M Buy
111,023
+19,889
+22% +$284K 0.01% 1104
2025
Q1 		$1.2M Sell
91,134
-3,109
-3% -$42.9K 0.01% 1281
2024
Q4 		$1.49M Buy
94,243
+2,718
+3% +$40.8K 0.01% 1145
2024
Q3 		$1.45M Buy
91,525
+2,820
+3% +$45.4K 0.01% 1162
2024
Q2 		$1.35M Buy
88,705
+3,700
+4% +$53K 0.01% 1139
2024
Q1 		$1.25M Sell
85,005
-6,155
-7% -$89.9K 0.01% 1146
2023
Q4 		$1.27M Buy
+91,160
New +$1.22M 0.01% 948

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Pathstone Holdings's RDY Position: Q2 2026 in Review

Pathstone Holdings reduced its Dr. Reddy's Laboratories (RDY) stake by 14% in Q2 2026, selling an estimated $207K and leaving 95,197 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1339.

Pathstone Holdings first reported a position in RDY in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.67M in Q2 2025. 238 funds tracked by Wall St. Rank hold RDY as of Q2 2026.

  • Pathstone Holdings held 95,197 shares of Dr. Reddy's Laboratories worth $1.38M as of Q2 2026.
  • Pathstone Holdings sold 15,312 Dr. Reddy's Laboratories shares in Q2 2026, an estimated $207K.
  • Dr. Reddy's Laboratories made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1339 holding.
  • Pathstone Holdings first reported a position in Dr. Reddy's Laboratories in Q4 2023 and has held it in 11 quarters since.
  • Pathstone Holdings's Dr. Reddy's Laboratories position peaked at $1.67M in Q2 2025.
  • 238 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.